Responsive image

Common name

(3S,4R)-tetrahydrofuran-3,4-diol

IUPAC name

(3S,4R)-tetrahydrofuran-3,4-diol

SMILES

O1CC(C(C1)O)O

Common name

(3S,4R)-tetrahydrofuran-3,4-diol

IUPAC name

(3S,4R)-tetrahydrofuran-3,4-diol

SMILES

O1CC(C(C1)O)O

INCHI

InChI=1S/C4H8O3/c5-3-1-7-2-4(3)6/h3-6H,1-2H2/t3-,4+

FORMULA

C4H8O3

Responsive image

Common name

(3S,4R)-tetrahydrofuran-3,4-diol

IUPAC name

(3S,4R)-tetrahydrofuran-3,4-diol





Molecular weight

104.105

clogP

-0.109

clogS

0.954

Frequency

0.0048





HBond Acceptor

3

HBond Donor

2

Total Polar
Surface Area

49.69

Number of Rings

1

Rotatable Bond

0

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00011 S-Adenosylmethionine Responsive image Dietary Supplements; Micronutrients; Supplements; CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); For the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis.Also as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
FDBD00023 Adenosine monophosphate Responsive image Dietary Supplements; Micronutrients; Supplements; For nutritional supplementation, also for treating dietary shortage or imbalance.
FDBD00060 Adenosine triphosphate Responsive image Dietary Supplements; Micronutrients; Supplements; For nutritional supplementation, also for treating dietary shortage or imbalance.
FDBD00327 Framycetin Responsive image Anti-Bacterial Agents; Aminoglycosides; Antibiotics; Respiratory System; Ophthalmologicals; Sensory Organs; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Dermatologicals; Nasal Preparations; Antiinfectives; Medicated Dressings With Antiinfectives; Medicated Dressings; Aminoglycoside Antibacterials; For the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis. For the prophylaxis of ocular infections following foreign body removal.
FDBD00503 Inulin Responsive image Diagnostic Agents; Tests for Renal Function and Ureteral Injuries; Historically used in an important medical test of renal function, specifically a measure of glomerular filtration rate. Sometimes used to help relieve symptoms of diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia.
FDBD00505 Adenosine Responsive image Anti-Arrhythmia Agents; Analgesics; Vasodilator Agents; Cardiovascular Agents; Cardiovascular System; Cardiac Therapy; Purinergic P1 Receptor Agonists; Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
FDBD00673 Ribavirin Responsive image Antiviral Agents; Antimetabolites; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV).
FDBD00784 Azacitidine Responsive image Antineoplastic Agents; Immunosuppressive Agents; Enzyme Inhibitors; Antimetabolites; Antimetabolites, Antineoplastic; Antineoplastic and Immunomodulating Agents; Pyrimidine Analogues; For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
FDBD00848 Neomycin Responsive image Anti-Bacterial Agents; Protein Synthesis Inhibitors; Aminoglycosides; Antibiotics; Blood and Blood Forming Organs; Respiratory System; Ophthalmologicals; Sensory Organs; Throat Preparations; Genito Urinary System and Sex Hormones; Alimentary Tract and Metabolism; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Stomatological Preparations; Dermatologicals; Blood Substitutes and Perfusion Solutions; Irrigating Solutions; Antiinfectives; Antibacterials for Intramammary Use; Antidiarrheals, Intestinal Anti-Inflammatory/antiinfective Agents; Antiinfectives and Antiseptics for Local Oral Treatment; Otologicals; Antibiotics for Topical Use; Antiinfectives and Antiseptics for Intrauterine Use; Ophthalmological and Otological Preparations; Aminoglycoside Antibacterials; Intestinal Antiinfectives; Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).
FDBD01196 Paromomycin Responsive image Anti-Bacterial Agents; Amebicides; Antibiotics; Alimentary Tract and Metabolism; Antidiarrheals, Intestinal Anti-Inflammatory/antiinfective Agents; Intestinal Antiinfectives; For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
14 , 2
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
1hp0_ligand_frag_1.mol2 1hp0 1 -6.49 C1[C@H]([C@H](CO1)O)O 7
1ctu_ligand_frag_1.mol2 1ctu 1 -6.27 C1OC[C@H]([C@H]1O)O 7
1af2_ligand_frag_1.mol2 1af2 1 -6.23 C1OC[C@@H]([C@@H]1O)O 7
2wr8_ligand_frag_5.mol2 2wr8 1 -6.21 C1OC[C@@H]([C@@H]1O)O 7
4kxl_ligand_frag_3.mol2 4kxl 1 -6.21 C1OC[C@H]([C@H]1O)O 7
4kxm_ligand_frag_3.mol2 4kxm 1 -6.20 C1OC[C@@H]([C@@H]1O)O 7
1ctt_ligand_frag_1.mol2 1ctt 1 -6.19 C1[C@@H]([C@@H](CO1)O)O 7
2b1i_ligand_frag_1.mol2 2b1i 1 -6.19 C1OC[C@H]([C@H]1O)O 7
2xaf_ligand_frag_3.mol2 2xaf 1 -6.17 C1OC[C@@H]([C@@H]1O)O 7
1m9n_ligand_frag_1.mol2 1m9n 1 -6.16 C1OC[C@@H]([C@@H]1O)O 7
744 , 75